Taiwan · Delayed Price · Currency is TWD Libo Pharma Statistics
Total Valuation
Libo Pharma has a market cap or net worth of TWD 2.21 billion. The enterprise value is 1.57 billion.
| Market Cap | 2.21B |
| Enterprise Value | 1.57B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Libo Pharma has 75.24 million shares outstanding. The number of shares has increased by 34.43% in one year.
| Current Share Class | 75.24M |
| Shares Outstanding | 75.24M |
| Shares Change (YoY) | +34.43% |
| Shares Change (QoQ) | -10.40% |
| Owned by Insiders (%) | 7.23% |
| Owned by Institutions (%) | 10.80% |
| Float | 41.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.47 |
| P/TBV Ratio | 2.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 38.24, with a Debt / Equity ratio of 0.00.
| Current Ratio | 38.24 |
| Quick Ratio | 31.89 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -15,182.56 |
Financial Efficiency
Return on equity (ROE) is -52.97% and return on invested capital (ROIC) is -34.54%.
| Return on Equity (ROE) | -52.97% |
| Return on Assets (ROA) | -32.74% |
| Return on Invested Capital (ROIC) | -34.54% |
| Return on Capital Employed (ROCE) | -42.36% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 31 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 30.26 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 46.04 |
| Average Volume (20 Days) | 51,550 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -379.56M |
| Pretax Income | -363.10M |
| Net Income | -363.10M |
| EBITDA | -357.69M |
| EBIT | -379.56M |
| Earnings Per Share (EPS) | -4.88 |
Balance Sheet
The company has 642.01 million in cash and 625,000 in debt, with a net cash position of 641.38 million or 8.53 per share.
| Cash & Cash Equivalents | 642.01M |
| Total Debt | 625,000 |
| Net Cash | 641.38M |
| Net Cash Per Share | 8.53 |
| Equity (Book Value) | 896.02M |
| Book Value Per Share | 11.91 |
| Working Capital | 751.83M |
Cash Flow
In the last 12 months, operating cash flow was -446.12 million and capital expenditures -686,000, giving a free cash flow of -446.80 million.
| Operating Cash Flow | -446.12M |
| Capital Expenditures | -686,000 |
| Depreciation & Amortization | 21.88M |
| Net Borrowing | -1.58M |
| Free Cash Flow | -446.80M |
| FCF Per Share | -5.94 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Libo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.43% |
| Shareholder Yield | -34.43% |
| Earnings Yield | -16.42% |
| FCF Yield | -20.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |